ERBB2 and gastric cancer: This was further followed by the DESTINY-Gastric 003 trial, which enrolled patients with HER2 positive (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization-positive by local testing) EC/GEJC/GC patients, globally, irrespective of PD-L1 status.